

PNS 2020 Virtual Symposium Agenda
October 15, 2020 | 12pm EST/9am PST

Title

The Burden of hATTR Amyloidosis: Evaluating Recent Literature on the Polyneuropathy of the Disease and Patisiran

Summary

Please join our expert faculty panel to learn about the impact of hATTR amyloidosis on patients' quality of life and review the latest publications in the field of the disease and on patisiran.

Objectives

- Highlight the impact hATTR amyloidosis has on patients' quality of life and review recent literature in the field
- Provide an overview of the recent data of patisiran on patient quality of life measures and autonomic manifestations in hATTR amyloidosis with polyneuropathy, in the context of the Phase 3 APOLLO study
- Discuss the interim safety and efficacy data of patisiran in the Global Open Label Extension study

Chair

Dr. Michael Polydefkis

Agenda

Time	Topics	Speaker
5 min	Welcome and Introduction	Dr. Michael Polydefkis
15 min	From Monitoring to Treatment: Addressing Polyneuropathy Progression in Patients	Dr. Michelle Mezei
15 min	Quality of life and autonomic outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis	Dr. Alejandra Gonzalez Duarte
15 min	Efficacy and Safety of Long-term Treatment with Patisiran: The Global Open-Label Extension Study	Dr. Michael Polydefkis
10 min	Question & Answer	All Faculty Panelists

For Healthcare Professionals Only

Symposium is organized and funded by Alnylam Pharmaceuticals
Symposium will include information on Alnylam medicines

For UK physicians, please use the following link to access the patisiran Abbreviated Prescribing Information:

<http://www.alnylam.co.uk/UK-Patisiran-API>